Stockholders Approve 1.5 Million Share Increase for Equity Incentive Plan

summarizeSummary

Shareholders approved adding 1.5 million shares to X4 Pharmaceuticals' equity incentive plan, enabling the company to use stock-based compensation for talent retention and recruitment.

check_boxKey Events

• Equity Incentive Plan Expanded

  Stockholders approved increasing the shares available under the Second Amended and Restated 2017 Equity Incentive Plan by 1,500,000 shares. This authorization was previously proposed in a DEF 14A filing on March 20, 2026.

• Potential Dilution

  If all 1,500,000 newly authorized shares were issued, it would represent a potential dilution of approximately 1.65% based on 90,919,696 shares outstanding as of March 13, 2026.

• Director Elections & Auditor Ratification

  Three Class III director nominees (Gary J. Bridger, Françoise De Craecker, and Michael S. Wyzga) were elected to serve until the 2029 Annual Meeting. PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for 2026.

• Executive Compensation Approved

  Stockholders approved, on a non-binding, advisory basis, the compensation of the company's named executive officers.

auto_awesomeAnalysis

X4 Pharmaceuticals' stockholders approved an increase of 1.5 million shares for its equity incentive plan. This authorization, representing approximately 1.65% potential dilution based on current outstanding shares, allows the company to continue attracting and retaining key talent through equity compensation. This follows the company's recent positive news regarding EU marketing authorization for XOLREMDI and a 12-month cash runway, making the ability to offer competitive equity incentives important for long-term growth.